130 related articles for article (PubMed ID: 30039904)
21. [New findings in Noonan syndrome and Leopard syndrome: activating mutations in RAF-1 and SOS-1].
Dereure O
Ann Dermatol Venereol; 2008; 135(8-9):624-5. PubMed ID: 18789305
[No Abstract] [Full Text] [Related]
22. [Arnold-Chiari malformation in Noonan syndrome and other syndromes of the RAS/MAPK pathway].
Ejarque I; Millán-Salvador JM; Oltra S; Pesudo-Martínez JV; Beneyto M; Pérez-Aytés A
Rev Neurol; 2015 May; 60(9):408-12. PubMed ID: 25912702
[TBL] [Abstract][Full Text] [Related]
23. Multiple spinal nerve enlargement and SOS1 mutation: Further evidence of overlap between neurofibromatosis type 1 and Noonan phenotype.
Santoro C; Giugliano T; Melone MAB; Cirillo M; Schettino C; Bernardo P; Cirillo G; Perrotta S; Piluso G
Clin Genet; 2018 Jan; 93(1):138-143. PubMed ID: 28456002
[TBL] [Abstract][Full Text] [Related]
24. Differential allelic expression of SOS1 and hyperexpression of the activating SOS1 c.755C variant in a Noonan syndrome family.
Moncini S; Bonati MT; Morella I; Ferrari L; Brambilla R; Riva P
Eur J Hum Genet; 2015 Nov; 23(11):1531-7. PubMed ID: 25712082
[TBL] [Abstract][Full Text] [Related]
25. Ulerythema ophryogenes, a rarely reported cutaneous manifestation of noonan syndrome: case report and review of the literature.
Li K; Ann Thomas M; Haber RM
J Cutan Med Surg; 2013; 17(3):212-8. PubMed ID: 23673306
[TBL] [Abstract][Full Text] [Related]
26. SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome.
Zenker M; Horn D; Wieczorek D; Allanson J; Pauli S; van der Burgt I; Doerr HG; Gaspar H; Hofbeck M; Gillessen-Kaesbach G; Koch A; Meinecke P; Mundlos S; Nowka A; Rauch A; Reif S; von Schnakenburg C; Seidel H; Wehner LE; Zweier C; Bauhuber S; Matejas V; Kratz CP; Thomas C; Kutsche K
J Med Genet; 2007 Oct; 44(10):651-6. PubMed ID: 17586837
[TBL] [Abstract][Full Text] [Related]
27. Acute lymphoblastic leukemia developing in a patient with Noonan syndrome harboring a PTPN11 germline mutation.
Sakamoto K; Imamura T; Asai D; Goto-Kawashima S; Yoshida H; Fujiki A; Furutani A; Ishida H; Aoki Y; Hosoi H
J Pediatr Hematol Oncol; 2014 Mar; 36(2):e136-9. PubMed ID: 24072241
[TBL] [Abstract][Full Text] [Related]
28. Noonan syndrome patient-specific induced cardiomyocyte model carrying SOS1 gene variant c.1654A>G.
Gurusamy N; Rajasingh S; Sigamani V; Rajasingh R; Isai DG; Czirok A; Bittel D; Rajasingh J
Exp Cell Res; 2021 Mar; 400(1):112508. PubMed ID: 33549576
[TBL] [Abstract][Full Text] [Related]
29. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway.
Tidyman WE; Rauen KA
Expert Rev Mol Med; 2008 Dec; 10():e37. PubMed ID: 19063751
[TBL] [Abstract][Full Text] [Related]
30. Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome–associated Sos1 mutation.
Chen PC; Wakimoto H; Conner D; Araki T; Yuan T; Roberts A; Seidman C; Bronson R; Neel B; Seidman JG; Kucherlapati R
J Clin Invest; 2010 Dec; 120(12):4353-65. PubMed ID: 21041952
[TBL] [Abstract][Full Text] [Related]
31. Noonan and cardio-facio-cutaneous syndromes: two clinically and genetically overlapping disorders.
Nyström AM; Ekvall S; Berglund E; Björkqvist M; Braathen G; Duchen K; Enell H; Holmberg E; Holmlund U; Olsson-Engman M; Annerén G; Bondeson ML
J Med Genet; 2008 Aug; 45(8):500-6. PubMed ID: 18456719
[TBL] [Abstract][Full Text] [Related]
32. Mutation analysis of the genes involved in the Ras-mitogen-activated protein kinase (MAPK) pathway in Korean patients with Noonan syndrome.
Lee ST; Ki CS; Lee HJ
Clin Genet; 2007 Aug; 72(2):150-5. PubMed ID: 17661820
[TBL] [Abstract][Full Text] [Related]
33. Comprehensive genetic analysis of overlapping syndromes of RAS/RAF/MEK/ERK pathway.
Tumurkhuu M; Saitoh M; Sato A; Takahashi K; Mimaki M; Takita J; Takeshita K; Hama T; Oka A; Mizuguchi M
Pediatr Int; 2010 Aug; 52(4):557-62. PubMed ID: 20030748
[TBL] [Abstract][Full Text] [Related]
34. PHENOTYPIC CONSEQUENCES AND THE MALIGNANCY RISK IN FAMILIAL NOONAN SYNDROME DUE TO A RARE P.S427G RAF1 MUTATION.
Pelc M; Ciara E; Jezela-Stanek A; Krajewska-Walasek M
Genet Couns; 2016; 27(3):325-333. PubMed ID: 30204961
[TBL] [Abstract][Full Text] [Related]
35. Noonan syndrome and related disorders: a review of clinical features and mutations in genes of the RAS/MAPK pathway.
Jorge AA; Malaquias AC; Arnhold IJ; Mendonca BB
Horm Res; 2009; 71(4):185-93. PubMed ID: 19258709
[TBL] [Abstract][Full Text] [Related]
36. PTPN11 and KRAS gene analysis in patients with Noonan and Noonan-like syndromes.
Brasil AS; Pereira AC; Wanderley LT; Kim CA; Malaquias AC; Jorge AA; Krieger JE; Bertola DR
Genet Test Mol Biomarkers; 2010 Jun; 14(3):425-32. PubMed ID: 20578946
[TBL] [Abstract][Full Text] [Related]
37. Spectrum of mutations and genotype-phenotype analysis in Noonan syndrome patients with RIT1 mutations.
Yaoita M; Niihori T; Mizuno S; Okamoto N; Hayashi S; Watanabe A; Yokozawa M; Suzumura H; Nakahara A; Nakano Y; Hokosaki T; Ohmori A; Sawada H; Migita O; Mima A; Lapunzina P; Santos-Simarro F; García-Miñaúr S; Ogata T; Kawame H; Kurosawa K; Ohashi H; Inoue S; Matsubara Y; Kure S; Aoki Y
Hum Genet; 2016 Feb; 135(2):209-22. PubMed ID: 26714497
[TBL] [Abstract][Full Text] [Related]
38. Severe hypertrophic cardiomyopathy in Noonan syndrome-consider sequencing genes encoding sarcomeric proteins.
McBride KL
Am J Med Genet A; 2013 Jan; 161A(1):230-1. PubMed ID: 23239527
[No Abstract] [Full Text] [Related]
39. Integrating Functional Analysis in the Next-Generation Sequencing Diagnostic Pipeline of RASopathies.
Leung GKC; Luk HM; Tang VHM; Gao WW; Mak CCY; Yu MHC; Wong WL; Chu YWY; Yang WL; Wong WHS; Ma ACH; Leung AYH; Jin DY; Chan KYK; Allanson J; Lo IFM; Chung BHY
Sci Rep; 2018 Feb; 8(1):2421. PubMed ID: 29402968
[TBL] [Abstract][Full Text] [Related]
40. A further patient with Noonan syndrome due to a SOS1 mutation and rhabdomyosarcoma.
Hastings R; Newbury-Ecob R; Ng A; Taylor R
Genes Chromosomes Cancer; 2010 Oct; 49(10):967-8. PubMed ID: 20607846
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
